{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"DoR is defined as the time from first documented evidence or PR or better until progressive disease per IMWG or death due to progressive disease among participants who achieve confirmed partial response or better.","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 0.5 mg/kg belantamab mafodotin intravenous (IV) infusion as powder for solution once every 4 weeks (Q4W) infused over 30- 60 minutes on day 1 of each 28-day cycle in combination with 100 mg Nirogacestat administered orally twice a day (BID) up to Day 28. Along with 4 mg Pomalidomide orally per day (QD) on Days 1-21 of each 28-day cycle and Dexamethasone 40mg (20 mg for participants \\>75 years old or BMI \\<18.5 kg/m\\^2) administered orally on days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG000","title":"0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone"}],"populationDescription":"No participants were enrolled as CE Phase was not initiated due to business strategic reason.","reportingStatus":"POSTED","timeFrame":"Up to 137 weeks","title":"CE Phase: Duration of Response (DoR)","type":"SECONDARY"}